Impact of Adjuvant Chemotherapy on Variant Histology of Upper Tract Urothelial Carcinoma: A Propensity Score-Matched Cohort Analysis

Chi-Wen Lo1,2, Wei-Ming Li3,4,5,6,7, Hung-Lung Ke3,4,5,6,7, Yi-Huei Chang8,9,10, Hsi-Chin Wu8,9,10, I-Hsuan Alan Chen11, Jen-Tai Lin11, Chao-Yuan Huang11, Chung-Hsin Chen12, Jen-Shu Tseng13,14,15, Wun-Rong Lin13,14,15, Yuan-Hong Jiang16, Yu-Khun Lee16, Chung-You Tsai17,18, Shiu-Dong Chung17,19,20, Thomas Y. Hsueh21,22,23, Allen W. Chiu21,22,23, Yeong-Chin Jou24,25, Ian-Seng Cheong24,25, Yung-Tai Chen26, Jih-Sheng Chen26, Bing-Juin Chang27,28,29, Chih-Chin Yu30,31,32, Wei Yu Lin30,31,32, Chia-Chang Wu33,34, Chuan-Shu Chen35,36,37, Han-Yu Weng38 and Yao-Chou Tsai1,2*

Background: The advantage of adjuvant chemotherapy for upper urinary tract urothelial cancer (UTUC) has been reported, whereas its impact on upper tract cancer with variant histology remains unclear. We aimed to answer the abovementioned question with our real-world data.

1 Division of Urology, Department of Surgery, Taipei Tzuchi Hospital, The Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, 2 School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan, 3 Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 4 Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 5 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 6 Department of Urology, Ministry of Health and Welfare Pingtung Hospital, Pingtung, Taiwan, 7 Cohort Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan, 8 Department of Urology, China Medical University Hospital, Taichung, Taiwan, 9 School of Medicine, China Medical University, Taichung, Taiwan, 10 Department of Urology, China Medical University Beigang Hospital, Yunlin, Taiwan, 11 Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 12 Department of Urology, National Taiwan University Hospital, College of Medicine, and National Taiwan University Hospital, Taipei, Taiwan, 13 Department of Urology, MacKay Memorial Hospital, Taipei, Taiwan, 14 Department of Medicine, Mackay Medical College, Taipei, Taiwan, 15 Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan, 16 Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan, 17 Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, Taiwan, 18 Department of Healthcare Information and Management, Ming Chuan University, Taoyuan, Taiwan, 19 Department of Nursing, College of Healthcare and Management, Asia Eastern University of Science and Technology, New Taipei City, Taiwan, 20 General Education Center, Eastern University of Science and Technology, New Taipei City, Taiwan, 21 Division of Urology, Department of Surgery, Taipei City Hospital Renai Branch, Taipei, Taiwan, 22 Department of Urology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, 23 College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, 24 Department of Urology, Dittmann Medical Foundation Chiai Christian Hospital, Chiai, Taiwan, 25 Department of Health and Nutrition Biotechnology, Asian University, Taichung, Taiwan, 26 Department of Urology, Taiwan Adventist Hospital, Taipei, Taiwan, 27 College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan, 28 Department of Urology, Cardinal Tien Hospital, New Taipei City, Taiwan, 29 Department of Life Science, College of Science, National Taiwan Normal University, Taipei, Taiwan, 30 Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chia-Yi, Taiwan, 31 Chang Gung University of Science and Technology, Chia-Yi, Taiwan, 32 Department of Medicine, Chang Gung University, Taoyuan, Taiwan, 33 Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, 34 Taipei Medical University Research Center of Urology and Kidney (TMU-ROK), Taipei Medical University, Taipei, Taiwan, 35 Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, 36 Institute of Medicine, Chung Shan Medical University, Taichung City, Taiwan, 37 Department of Senior Citizen Service Management, National Taichung University of Science and Technology, Taichung City, Taiwan, 38 Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
**Design, Setting, and Participants:** Patients who underwent radical nephroureterectomy (RNU) and were confirmed to have variant UTUC were retrospectively evaluated for eligibility of analysis. In the Taiwan UTUC Collaboration database, we identified 245 patients with variant UTUC among 3,109 patients with UTUC who underwent RNU after excluding patients with missing clinicopathological information.

**Intervention:** Those patients with variant UTUC were grouped based on their history of receiving adjuvant chemotherapy or not.

**Outcome Measurements and Statistical Analysis:** Propensity score matching was used to reduce the treatment assignment bias. Multivariable Cox regression model was used for the analysis of overall, cancer-specific, and disease-free survival.

**Results and Limitations:** For the patients with variant UTUC who underwent adjuvant chemotherapy compared with those without chemotherapy, survival benefit was identified in overall survival in univariate analysis (hazard ratio (HR), 0.527; 95% confidence interval (CI), 0.285–0.973; \( p = 0.041 \)). In addition, in multivariate analysis, patients with adjuvant chemotherapy demonstrated significant survival benefits in cancer-specific survival (OS; HR, 0.454; CI, 0.208–0.988; \( p = 0.047 \)), and disease-free survival (DFS; HR, 0.324; 95% CI, 0.155–0.677; \( p = 0.003 \)). The main limitations of the current study were its retrospective design and limited case number.

**Conclusions:** Adjuvant chemotherapy following RNU significantly improved cancer-related survivals in patients with UTUC with variant histology.

**Keywords:** adjuvant chemotherapy, nephroureterectomy, upper urinary tract urothelial cancer, variant histology, UTUC

---

**INTRODUCTION**

Upper urinary tract urothelial carcinoma (UTUC) is a rare cancer and accounts for only 5%–10% of genitourinary urothelial cancers (UC) in Western countries (1). UTUC with nontransitional-cell variant histopathology (vUTUC) is an even rarer situation, accounting for 8%–24% among historical UTUC series where the patients were managed with radical nephroureterectomy (RNU) (1–9). vUTUC is commonly associated with more adverse pathological features and advanced disease status at presentation when compared with those of UTUC with pure urothelial pathology (pUTUC) (1–4, 6–9). In addition, patients with vUTUC are usually associated with worse outcomes in overall (OS), cancer-specific (CSS), and disease-free survival (DFS) (1). Therefore, a variant histopathologic feature in UTUC is an important prognostic factor that should be recognized for subsequent treatment planning and disease surveillance.

Bladder UC shares several similar histopathological and prognostic features with UTUC. Variant histology in bladder UC is also associated with adverse pathological features and poor outcomes (10–12). The poor outcomes of variant histology bladder UC raised the speculation of whether perioperative chemotherapy will improve outcomes in this distinct subset of bladder UC. Neoadjuvant chemotherapy has been reported to improve survival outcomes with variant histologic features in bladder UC (10, 13). A recent meta-analysis revealed that good outcomes are associated with chemotherapy for small-cell and micropapillary variants, while chemotherapy has a potential role in squamous cell and adenocarcinoma variants (13).

The success of adjuvant chemotherapy in variant bladder UC certainly led to the speculation whether vUTUC would benefit from adjuvant chemotherapy, but the study of the more aggressive vUTUC is usually limited by its even rare presentation. Although the safety and efficacy of adjuvant chemotherapy for UTUC had been confirmed in the Perioperative Chemotherapy Versus Surveillance in Upper Tract urothelial cancer (Peri-UC) trial, the outcomes of adjuvant chemotherapy for patients with vUTUC remain scarce (14). There is no randomized controlled trials (RCTs) or comparative trial focusing on the even rarer and more aggressive vUTUC. Therefore, we conducted a propensity score-matched study to examine the impact of adjuvant chemotherapy on vUTUC.

**MATERIAL AND METHODS**

**Data Source**

This UTUC registry database was conducted by the Taiwan UTUC Collaboration Group, a multicenter Internet-based...
registry partially sponsored by the Taiwan Urological Association. This retrospective study was reviewed and approved by the institutional review board (IRB No.: 063-X34-105), and the requirement of informed consent was waived due to its anonymous nature without any identifiable information in the database. The study protocols and methods were carried out in accordance with relevant guidelines and regulations.

Patient Selection
Patients who underwent RNU and were confirmed to have UTUC with variant histology were retrospectively evaluated for eligibility of analysis. Those patients with postoperative adjuvant chemotherapy were defined as systemic chemotherapy given within 4 months after RNU (15). There were 3,109 patients examined for eligibility, with 245 cases enrolled for final analysis (Figure 1). vUTUC was defined as those patients with upper urinary tract carcinoma who exhibited a nontransitional-cell histopathology type under pathological evaluation. The groups were categorized by vUTUC with adjuvant chemotherapy (vUTUC+C/T) and vUTUC without adjuvant chemotherapy (vUTUC–C/T). Those cases with neoadjuvant chemotherapy or missing histology/staging information, chemotherapeutic agents, and survival information were excluded.

Pathological Evaluation
The histopathological diagnosis and staging of RNU specimens were reviewed by local genitourinary pathologists in each institution according to the 2010 American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging system, and histopathologic grading was made according to the 2015 WHO/ISUP recommendation grading system. The histopathological diagnosis of variant histology has been well accepted by the uropathological community, and the diagnostic criteria were described in the WHO classification of tumors (16).

Follow-Up
The follow-up schedule for patients was every 3–6 months in the 1st year after RNU and every 6–12 months thereafter. Cross-sectional imaging (computed tomography (CT) or/and magnetic resonance images (MRI)) was used to determine recurrence/progression-free statuses. Cystoscopy examination was used to determine urinary bladder recurrence. UTUC recurrence or metastasis was defined as local recurrence of tumor bed, regional lymph nodes, or distant metastasis.

Matching Methods
To address the imbalance of potential confounders between the control and treatment adjuvant groups, we matched treatment “adjuvant” groups using propensity scores. In the statistical analysis of observational data, propensity score matching (PSM) is a statistical matching technique that attempts to estimate the effect of a treatment, policy, or other intervention by accounting for the covariates that predict receiving the treatment. In each simulated dataset, we estimated the propensity score using a logistic regression model to regress treatment status on the baseline covariates. The propensity score model included lymphovascular invasion, surgical margin, and pathological stage. We then formed matched pairs between the control group managed by watch and wait and those who had treatment adjuvant using nearest-neighbor matching gender (tolerance levels: 0), age (tolerance levels: 5), and pathological stage. We then formed matched pairs between the control group managed by watch and wait and those who had treatment adjuvant using nearest-neighbor matching gender (tolerance levels: 0), age (tolerance levels: 5), and propensity score (tolerance levels: 0.01). Our study on propensity score matching is one-to-one or pair matching, in which pairs of control and treated subjects are formed, such that matched subjects have similar values of the propensity score.

Statistical Analysis
Demographic and clinicopathological differences between groups were compared using Pearson Chi-square with Bonferroni correction for categorical variables. The Kaplan–Meier estimator was used to estimate the rates of survival outcomes, and the survival curves were compared using the stratified log-rank test. Cox proportional hazard model was selected to assess the effect of the treatment groups on the survival outcomes, alone and after adjusting for potential confounders. Those clinicopathological variables were selected with stepwise regression then included in the multivariate analysis. All the univariate significant and nonsignificant relevant covariates should be put on the variable list to be selected. The significance levels for entry (SLE) and stay (SLS) are suggested to be set to 0.05 and 0.1, respectively. The best regression model is then identified manually by reducing the significant levels to 0.05, corresponding to the chosen level. All statistical assessments were two-tailed and considered statistically significant at \( p < 0.05 \). Statistical analyses were carried out with IBM SPSS statistical software version 22. The description of statistical methods was based on the standard format of statistical analysis of the Taiwan UTUC collaboration group.

FIGURE 1 | Flow diagram of case recruitment process.
RESULTS

Study Cohort and Baseline Characteristics

In total, 245 patients who underwent RNU with variant histology were enrolled for final analysis. The recorded variant histopathological types included sarcomatoid differentiation (16.3%), squamous cell carcinoma (53.1%), adenocarcinoma (7.7%), neuroendocrine differentiation (4.1%), and mixed variant histology (7.7%). In total, 75 of 245 (30.6%) patients with vUTUC underwent adjuvant chemotherapy. Table 1 summarizes the baseline clinical characteristics of the 169 cases in the vUTUC-C/T group and 75 cases in the vUTUC+C/T group before matching. Significant bias was observed in baseline characteristics in gender, age, comorbidity, tumor multiplicity, lymphovascular invasion status, pT/N stage, and preoperative renal function status before matching. After PSM, we derived 1:1 50 paired cohorts for vUTUC with and without adjuvant chemotherapy. These two groups were well-matched for all confounding variables (Table 2). In addition, there was no significant difference in the distribution of variant histology subtypes. The median cycles of adjuvant chemotherapy for the vUTUC+C/T group were 4 (interquartile range: 3–5). The most

| Variables | UC with variants/no C/T (N = 169) | UC with variants/C/T (N = 75) | p-value* |
|-----------|----------------------------------|-------------------------------|----------|
| Gender    |                                  |                               |          |
| Men       | 56 (33.1)                        | 45 (60.0)                     | <0.001** |
| Women     | 113 (66.9)                       | 30 (40.0)                     |          |
| Age       |                                  |                               |          |
| <70       | 65 (38.5)                        | 51 (68.0)                     | <0.001** |
| ≥70       | 104 (61.5)                       | 24 (32.0)                     |          |
| Comorbidity|                                 |                               |          |
| Coronary artery disease | 14 (8.3) | 6 (7.0) | 0.918 |
| Arrhythmia | 9 (5.3) | 2 (2.0) | 0.346 |
| Hypertension | 97 (57.4) | 28 (36.0) | 0.003** |
| Diabetes   | 51 (30.2)                        | 18 (23.0)                     | 0.296    |
| Gouty arthritis | 3 (1.8) | 3 (3.0) | 0.309 |
| Gastrointestinal disorder | 21 (12.4) | 8 (10.0) | 0.670 |
| 2nd malignancy (not urothelial cancer) | 27 (16.0) | 11 (14.0) | 0.764 |
| Tumor location |                                  |                               |          |
| Renal pelvis  | 87 (51.5) | 35 (46.0) | 0.593 |
| Ureter       | 47 (27.8)                        | 21 (27.0)                     |          |
| Renal pelvis + ureter | 36 (20.7) | 20 (26.0) |          |
| Tumor size  |                                  |                               |          |
| <3 cm       | 56 (33.1)                        | 26 (34.0)                     | 0.869    |
| ≥3 cm       | 113 (66.9)                       | 50 (65.0)                     |          |
| RNU histology |                                 |                               |          |
| Low grade   | 5 (3.0)                          | 0 (0.0)                       | 0.499    |
| High grade  | 158 (93.5)                       | 73 (97.0)                     |          |
| Gx          | 4 (2.4)                          | 1 (1.0)                       |          |
| G2          | 1 (0.6)                          | 1 (1.0)                       |          |
| Well-differentiated | 1 (0.6) | 0 (0.0) |          |
| Multiplicity |                                 |                               |          |
| Not available | 0 (0.0) | 1 (1.0) | 0.018* |
| No          | 115 (68.9)                       | 39 (52.0)                     |          |
| Yes         | 52 (31.1)                        | 35 (46.0)                     |          |
| CIS         |                                  |                               |          |
| No          | 133 (78.7)                       | 58 (76.0)                     | 0.677    |
| Yes         | 36 (21.3)                        | 18 (23.0)                     |          |
| Lymphovascular invasion |              |                               |          |
| No          | 112 (66.3)                       | 38 (50.0)                     | 0.016*   |
| Yes         | 57 (33.7)                        | 39 (50.0)                     |          |
| Surgical margin |                                 |                               |          |
| Free        | 150 (88.8)                       | 67 (88.0)                     | 0.891    |
| Positive    | 19 (11.2)                        | 9 (11.0)                      |          |
| Tumor necrosis |                                 |                               |          |
| No          | 108 (64.3)                       | 44 (58.0)                     | 0.403    |
| Yes         | 60 (35.7)                        | 31 (41.0)                     |          |
| Synchronous bladder tumor |             |                               |          |
| No          | 142 (84.5)                       | 61 (80.0)                     | 0.684    |

(Continued)
The used chemotherapeutic regimen was gemcitabine plus cisplatin, followed by gemcitabine plus carboplatin, and then MVAC regimen (methotrexate, vinblastine, doxorubicin plus cisplatin). At the end of our follow-up, forty-three of 100 cases had an event in overall survival and 38 of 100 cases had at least one event in disease progression.

**Survival Analyses: Variant UTUC Without Chemotherapy vs. Variant UTUC With Chemotherapy**

The median follow-up period was comparable between the vUTUC −C/T and vUTUC+C/T groups (22.2 and 29.1 months, respectively) (Table 1). In the univariate analyses, survival difference was only identified in overall survival (hazard ratio (HR), 0.527; 95% confidence interval (CI), 0.285–0.973; \( p = 0.041 \)) (Table 3). However, in multivariate analyses, after adjusting with confounding factors selected with stepwise selection, significant survival benefit was found in disease-free survival (DFS) and cancer-specific survival (CSS) for the vUTUC+C/T patients (Tables 4 and 5). In brief, patients with variant histology who underwent adjuvant chemotherapy was associated with significant survival benefit in DFS (HR, 0.324; 95% CI, 0.155–0.677; \( p = 0.003 \)) and CSS (HR, 0.454; 95% CI, 0.208–0.988; \( p = 0.047 \)). LVI was the common independent risk factor for CSS and DFS. Positive surgical margin status is the independent risk factor for DFS (HR, 6.047; 95% CI, 1.554–23.53; \( p = 0.009 \)).

Comparison of Kaplan–Meier estimated survival curves between vUTUC with and without adjuvant chemotherapy in localized vUTUC (pT0−T2) and advanced vUTUC (pT3−T4) disease after PSM. The survival benefit was observed in OS and DFS for advanced vUTUC disease with adjuvant chemotherapy (Figures 2–4).

**DISCUSSION**

UTUC is an uncommon malignancy in Western countries, and UTUC associated with variant histology is even rarer; with an
TABLE 2 | Baseline demographic characteristics of patients with variant upper tract urothelial cancer (UTUC) undergoing radical nephroureterectomy (RNU) after matching.

| Variables                                                      | UC with variants/No C/T (N = 50) | UC with variants/C/T (N = 50) | p-value* |
|----------------------------------------------------------------|----------------------------------|--------------------------------|----------|
| N (%)                                                          | N (%)                            |                                |          |
| Gender                                                         |                                  |                                |          |
| Men                                                            | 23 (46.0)                        | 23 (46.0)                      | 1.000    |
| Women                                                          | 27 (54.0)                        | 27 (54.0)                      |          |
| Age                                                            |                                  |                                |          |
| <70                                                            | 27 (54.0)                        | 31 (62.0)                      | 0.418    |
| ≥70                                                            | 23 (46.0)                        | 19 (38.0)                      |          |
| Comorbidity                                                    |                                  |                                |          |
| Coronary artery disease                                       | 4 (8.0)                          | 4 (8.0)                        | 1.000    |
| Arrhythmia                                                     | 4 (8.0)                          | 2 (4.0)                        | 0.400    |
| Hypertension                                                   | 29 (58.0)                        | 19 (38.0)                      | 0.045*   |
| Diabetes                                                       | 15 (30.0)                        | 9 (18.0)                       | 0.160    |
| Gouty arthritis                                                | 1 (2.0)                          | 3 (6.0)                        | 0.307    |
| Gastrointestinal disorder                                     | 4 (8.0)                          | 6 (12.0)                       | 0.505    |
| 2nd malignancy (not urothelial cancer)                        | 9 (18.0)                         | 8 (16.0)                       | 0.790    |
| Tumor location                                                 |                                  |                                |          |
| Renal pelvis                                                   | 26 (52.0)                        | 19 (38.0)                      | 0.369    |
| Ureter                                                         | 12 (24.0)                        | 16 (32.0)                      |          |
| Renal pelvis + ureter                                          | 12 (24.0)                        | 15 (30.0)                      |          |
| Tumor size                                                     |                                  |                                |          |
| <3 cm                                                          | 12 (24.0)                        | 20 (40.0)                      | 0.086    |
| ≥3cm                                                          | 38 (76.0)                        | 30 (60.0)                      |          |
| RNU histology                                                  |                                  |                                |          |
| Low grade                                                     | 1 (2.0)                          | 0 (0.0)                        | 0.169    |
| High grade                                                    | 46 (92.0)                        | 48 (96.0)                      |          |
| Gx                                                             | 3 (6.0)                          | 0 (0.0)                        |          |
| G2                                                             | 0 (0.0)                          | 1 (2.0)                        |          |
| Multiplicity                                                   |                                  |                                |          |
| Not available                                                  | 0 (0.0)                          | 1 (2.0)                        | 0.158    |
| No                                                             | 33 (67.3)                        | 25 (50.0)                      |          |
| Yes                                                            | 16 (32.7)                        | 24 (48.0)                      |          |
| CIS                                                            |                                  |                                |          |
| No                                                             | 36 (72.0)                        | 38 (76.0)                      | 0.648    |
| Yes                                                            | 14 (28.0)                        | 12 (24.0)                      |          |
| Lymphovascular invasion                                       |                                  |                                |          |
| No                                                             | 30 (60.0)                        | 28 (56.0)                      | 0.685    |
| Yes                                                            | 20 (40.0)                        | 22 (44.0)                      |          |
| Surgical margin                                                |                                  |                                |          |
| Free                                                           | 47 (94.0)                        | 48 (96.0)                      | 0.646    |
| Positive                                                      | 3 (6.0)                          | 2 (4.0)                        |          |
| Tumor necrosis                                                 |                                  |                                |          |
| No                                                             | 29 (59.2)                        | 28 (56.0)                      | 0.749    |
| Yes                                                            | 20 (40.8)                        | 22 (44.0)                      |          |
| Synchronous bladder tumor                                     |                                  |                                |          |
| No                                                             | 40 (81.6)                        | 41 (82.0)                      | 0.999    |
| Yes                                                            | 9 (18.4)                         | 9 (18.0)                       |          |
| Pathological stage T                                          |                                  |                                |          |
| pTis/pTa/pT0/pT1/pT2                                           |                                  |                                |          |
| 7 (14.0)                                                       | 7 (14.0)                         | 1.000                           |
| pT3/pT4                                                       | 43 (86.0)                        | 43 (86.0)                      |          |
| Pathological stage N                                          |                                  |                                |          |
| pNO                                                           | 15 (30.0)                        | 13 (26.0)                      | 0.842    |
| pN+                                                           | 9 (18.0)                         | 11 (22.0)                      |          |
| pNx                                                           | 26 (52.0)                        | 26 (52.0)                      |          |
| eGFR                                                          |                                  |                                |          |
| ≥60                                                           | 15 (31.9)                        | 21 (44.7)                      | 0.203    |
| <60                                                           | 32 (68.1)                        | 26 (55.3)                      |          |
| Post-OP eGFR                                                   |                                  |                                |          |
| ≥60                                                           | 4 (9.1)                          | 7 (22.6)                       | 0.104    |
| <60                                                           | 40 (90.9)                        | 24 (77.4)                      |          |
| Histologic                                                    |                                  |                                |          |
| Sarcomatoid differentiation                                   | 8 (16.0)                         | 10 (20.0)                      | 0.692    |
| Squamous cell carcinoma                                       | 19 (38.0)                        | 25 (50.0)                      |          |
overall incidence of 13.4% among the worldwide UTUC cohort (1). The variant histology UTUC is an important adverse prognostic factor affecting most survival domains of UTUC (1, 17, 18). The squamous or/and glandular variant histology was associated with an even worse CSS compared with the other UTUC variants (1). Therefore, vUTUC is a warning and prognostic indicator that could require upfront systemic therapy which usually means chemotherapy before or after RNU for UTUC. Based on recent evidence, perioperative chemotherapy (neoadjuvant or adjuvant) is beneficial in prolonging survivals of UTUC (19–21). Although perioperative chemotherapy had been proved beneficial in bladder UC variants, currently available literature failed to reveal its benefit in vUTUC (3, 4, 8, 22).

Current evidence regarding the efficacy of systemic chemotherapy on vUTUC remained scarce in the literature. As UTUC and bladder UC shared several histological and prognostic features, the regimen of chemotherapy for UTUC commonly follows the classic regimen for bladder urothelial carcinoma. Hence, most urologists/oncologists adapt classic chemotherapy regimens of bladder UC for vUTUC. Hajiran et al. conducted a cohort study to compare the result of cystectomy followed by neoadjuvant chemotherapy. The patients with variant histology (micropapillary, plasmacytoid, nested variant, sarcomatoid, or neuroendocrine variant histology), had a comparable response rate as the pure urothelial carcinoma cohort (23). A National Cancer Database study showed neoadjuvant chemotherapy was associated with significant pathological downstaging for all histological variants (sarcomatoid, micropapillary, squamous, neuroendocrine, and adenocarcinoma) and overall survival improvement for patients with variant bladder UC (24). In addition, MIBC with micropapillary, plasmacytoid variant, or squamous/glandular differentiation should be treated with neoadjuvant chemotherapy according to the recommendation of the 2020 EAU-ESMO Consensus Statements (25). Therefore, there is a clear role of chemotherapy in bladder UC with histological variants. Hence, the current cisplatin-based chemotherapy regimen is potentially effective in urothelial carcinoma with variant histology, as UTUC deserved a prospective randomized trial to confirm our speculation.

There was a national cancer database study that analyzed survivals of the UTUC with variant histology in the renal pelvis after surgery (26). Being restricted to the limited clinicopathological information in the cancer database, it only revealed the survival benefit of adjuvant chemotherapy in patients with pure UTUC but not for the patients with UTUC variants. Indeed, several limitations would hamper the power of cancer database study, such as significant variations in regimen and cycles of chemotherapy, comorbidity of patients, and intergroup bias of adverse histologic factors. Based on our findings, several important clinicopathological factors were independently associated with the survivals of the variant UTUC cohort (Tables 3–5). The important clinicopathological data that include comorbidities, surgical margin status, tumor size, tumor location, and lymphovascular invasion were generally not available in the cancer database study, therefore, limited the power of a national cancer database study. Hence, a comprehensive clinicopathological database could help in clarifying the real-world strategies of cancer treatment.

Murakami and their colleagues reported a multi-institutional study where those patients with UTUC with variant histology is an independent risk factor for recurrence-free survival but not for CSS (6). In addition, those vUTUC with pT3 or higher T stage and/or positive lymph node status were indicated for adjuvant chemotherapy. However, due to its retrospective study design and very-limited case number (37 UTUC cases with variant histology), significant selection bias and low power to reveal the real impact of adjuvant chemotherapy. To the best of our knowledge, our study is currently the limited PSM cohort study for the impact of chemotherapy on vUTUC. The current

### TABLE 2 | Continued

| Variables | UC with variants/No C/T (N = 50) | UC with variants/C/T (N = 50) | p-value* |
|-----------|-----------------------------|----------------------------|---------|
| Adenocarcinoma | 5 (10.0) | 3 (6.0) | 0.623 |
| Neuroendocrine tumors | 3 (6.0) | 3 (6.0) | 0.790 |
| Mixed-cell type | 7 (14.0) | 4 (8.0) | 0.841 |
| Missing | 8 (16.0) | 10 (20.0) | 0.032 |
| Regimen of chemotherapy | | | |
| Gemcitabine and cisplatin | 2 (40.0) | 18 (40.0) | 0.623 |
| MVAC | 0 (0.0) | 2 (4.0) | |
| Taxane-based | 0 (0.0) | 1 (2.0) | |
| Carboplatin-based | 4 (40.0) | 13 (28.0) | |
| Others | 4 (40.0) | 11 (24.0) | |
| Bladder UC after RNU | | | |
| No | 42 (84.0) | 41 (82.0) | 0.790 |
| Yes | 8 (16.0) | 9 (18.0) | |
| Lymphadenectomy | | | |
| No | 27 (54.0) | 26 (52.0) | 0.841 |
| Yes | 23 (46.0) | 24 (48.0) | |

*aChi-squared test calculated for the different variables.
*bWilcoxon rank-sum test calculated for the difference in medians.
*p < 0.05.

RNU, radical nephroureterectomy; CIS, carcinoma in situ; MVAC, methotrexate, vinblastine, doxorubicin (Adriamycin), cisplatin.
study did not identify the beneficial effect of adjuvant chemotherapy in CSS and DFS for vUTUC (Tables 4 and 5). In addition, the presence of LVI, positive lymph node status, or a positive surgical margin are independent risk factors for poor survival outcomes, and adjuvant chemotherapy should be considered in this vUTUC after RNU.

The impact of the subtypes of variant histology has been reported in the literature without a definite conclusion. The micropapillary, squamous, and/or glandular subtypes were potentially associated with a worse CSS among patients with UTUC in a prior meta-analysis (1). However, the variant histology of adenocarcinoma had been reported to be associated with a better OS compared with pure UTUC in a cancer database study (26). This inconclusive result could be derived from excluding metastatic disease during case enrollment, therefore, excluding advanced variant adenocarcinoma subtype, which is commonly an important factor of lethal disease (27). According to our analysis,
different variant subtypes had comparable survival outcomes (Supplementary Figure S1). However, limited by the small case number in each subtype, the real impact of vUTUC subtypes should be clarified with a large-scale prospective study.

Lymphadenectomy has been recommended in RNU for UTUC for its potential survival benefit. In our matched cohort, 23 (46%) of 50 patients without adjuvant chemotherapy and 24 (48%) of 50 patients with chemotherapy underwent lymphadenectomy during RNU. As the role of extended lymphadenectomy remained controversial in UTUC treatment, extended or regional lymphadenectomy was only performed in selected cases who were clinically suspected of having advanced or nodal diseases; otherwise, lymphadenectomy was not performed in low-risk diseases. According to a large population cohort of 16,619 UTUCs, only 15.4% of cases underwent LND; therefore, the proportion of lymphadenectomy in our cohort is clearly not low when compared with the historical series (28).

Our cohort was extracted from the Taiwan UTUC registry which is a multicenter UTUC cohort that enrolled more than 4,000 UTUC cases in Taiwan. In the currently enrolled cohort, we identified 245 (7.2%) vUTUC among 3,043 Taiwan UTUC patients from 16 centers. The incidence of variant UTUC varied
among centers in Taiwan; it generally ranges from 2% to 13% with only two exceptions (only two centers had a high incidence of 20% which accounted for only 15% of the vUTUC cohort). According to a recent meta-analysis, vUTUC generally accounted for about 13% of all UTUC worldwide, and the incidence varied significantly among different centers (1). Therefore, significant interobserver variation in making the diagnosis of vUTUC is common and clearly inevitable in a multicenter study. Histology review has been recommended for the multicenter study of vUTUC; however, relevant studies remained extremely scarce in the literature. Last year, we randomly enrolled 154 UTUC cases from the Taiwan UTUC registry for histology review (29). Based on our review, 7.8% and 30.5% variant UTUC were identified by the local or the reviewing pathologist, respectively. Only a slight interobserver agreement was achieved with a kappa value of 0.168. However, whether the vUTUC has an impact on disease outcome, according to the univariate analysis, the presentation of variant histology was the only risk factor of DFS in the local pathology reviewed cohort, but not in the review pathology cohort. This could relate to an overdiagnosis of clinically nonsignificant vUTUC in the review pathologist’s cohort, therefore, certainly underestimating the impact of vUTUC on disease outcome. In summary, whether histology review of vUTUC is beneficial in disease outcome prediction for multicenter study remained controversial and need a prospective large cohort study in the future.

**LIMITATIONS**

This study has some limitations. First, the current study is still limited by the small sample size, the lack of the desired power level, and the effect size that does not correspond to the required sample size. Second, the pathology was not centrally reviewed; therefore, interobserver reporting bias was also considered one of the limitations. To minimize the impact of in-concordance of pathology between observers, we used a standardized histological report format which was approved by the Pathology Society of Taiwan based on the AJCC TNM staging system, and the principles of pathology management for urothelial cancer in the NCCN guidelines to ensure a standardized management protocol. In addition, genitourinary pathologists in Taiwan followed the same training program, specimen manipulation protocol, diagnostic criteria, standardized report template, and peer review system in each local institution to minimize the interobserver bias. Third, the retrospective nature of the study design is subject to selection bias. We attempted to account for this by the multi-institution enrollment, PSM, and multivariate Cox regression analyses with adjustment of confounding factors. In addition, cases with incomplete or missing information were excluded, except for some minor variables. Fourth, a lymphadenectomy was mainly performed in patients with clinical suspicious nodal diseases or advanced clinical stages, therefore, not routinely performed during RNU in Taiwan. Hence, the rate of pNx was as high as 45%–76%, which significantly undermined our ability to have further interpretation regarding the influence of the nodal status. Fifth, overall mortality and cancer-specific mortality could be partially overlapped in the primary comparison of matched cohorts. To minimize this effect, multivariate analysis was performed to adjust the confounders that could impact the survival. Finally, the lack of standard templates in reporting specific variant histology inevitably introduced further bias in the reported results (24).

**CONCLUSION**

In summary, adjuvant chemotherapy following RNU significantly improved CSS and DFS in patients with UTUC with a variant histology in the current propensity score-matched
study. Hence, the effect of adjuvant systemic chemotherapy deserves a further prospective, multi-institutional study to elucidate the optimal care for these rare and challenging patients.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

**AUTHOR CONTRIBUTIONS**

Conceptualization: H-YW and C-WL. Data curation: W-ML, H-LK, Y-HC, H-CW, I-TL, C-YH, H-CG, J-ST, W-RL, Y-HJ, Y-KL, C-YT, S-DC, TH, AC, Y-CJ, I-SC, Y-TC, J-SC, B-JC, C-CY, WL, C-CW, C-SC, and H-YW. Formal analysis: Y-CT. Methodology: W-ML and H-LK. Supervision: J-TL, AC, and Y-CJ. Writing—original draft: Y-CT. Writing—review and editing: Y-CT. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

**ACKNOWLEDGMENTS**

The authors would like to acknowledge all members of the Taiwan Upper Tract Urothelial Carcinoma Collaboration Group.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.843715/full#supplementary-material

**REFERENCES**

1. Mori K, Janisch F, Parizi MK, Mostafaei H, Lysenko I, Kimura S, et al. Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated With Nephroureterectomy: A Systematic Review and Meta-Analysis. *J Urol* (2020) 203:1075–84. doi: 10.1016/j.juro.2020.01.016
2. Rink M, Robinson BD, Green DA, Cha EK, Hansen I, Compljo E, et al. Impact of Histological Variants on Clinical Outcomes of Patients With Upper Urinary Tract Urothelial Carcinoma. *J Urol* (2012) 188:398–404. doi: 10.1016/j.juro.2012.04.009
3. Sakano S, Matsuyama H, Kamiryo Y, Hayashida S, Yamamoto N, Kameda Y, et al. Impact of Variant Histology on Disease Aggressiveness and Outcome After Nephroureterectomy in Japanese Patients With Upper Tract Urothelial Carcinoma. *Int J Clin Oncol* (2015) 20:362–8. doi: 10.1007/s10147-014-0721-3
4. Shihing Y, Turun S, Qiang W, Junhao L, Haichao Y, Shengqiang Q, et al. Effect of Concomitant Variant Histology on the Prognosis of Patients With Upper Urinary Tract Urothelial Carcinoma After Radical Nephroureterectomy. *Urol Oncol* (2015) 33:204.e209–216. doi: 10.1016/j.urolonc.2015.02.010
5. Kim JK, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH. Variant Histology as a Significant Predictor of Survival After Radical Nephroureterectomy in Patients With Upper Urinary Tract Urothelial Carcinoma. *Urol Oncol* (2017) 35:458.e459–468.e415. doi: 10.1016/j.urolonc.2017.02.010
6. Murakami Y, Matsumoto K, Ikeda M, Hirayama T, Utsunomiya T, Koguchi D, et al. Impact of Histologic Variants on the Oncological Outcomes of Patients With Upper Urinary Tract Cancers Treated With Radical Surgery: A Multi-Institutional Retrospective Study. *Int J Clin Oncol* (2019) 24:1412–8. doi: 10.1007/s10147-019-01486-y
7. Zamboni S, Foerster B, Abufaraj M, Seisen T, Roupnet M, Colin P, et al. Incidence and Survival Outcomes in Patients With Upper Urinary Tract Urothelial Carcinoma Diagnosed With Variant Histology and Treated With Nephroureterectomy. *BJU Int* (2019) 124:738–45. doi: 10.1111/bju.14751
8. Deuker M, Stolzenbach LF, Colla Ruvolo C, Nocera I, Tian Z, Roos FC, et al. Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma. *Clin Genitourin Cancer* (2020) 18(2):117–24. doi: 10.1016/j.clgc.2020.11.004
9. Rolim I, Henriquez V, Rolim N, Blanca A, Marques RC, Volavk M, et al. Clinicopathologic Analysis of Upper Urinary Tract Carcinoma With Variant Histology. *Virchows Arch* (2020) 477:111–20. doi: 10.1007/s00428-020-02745-4
10. Daneshmand S, Nazemi A. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. *Eur Urol Focus* (2020) 6:639–41. doi: 10.1016/j.euf.2020.04.011
11. Lobo N, Shariat SF, Guo CC, Fernandez ML, Kassouf W, Choudhury A, et al. What Is the Significance of Variant Histology in Urothelial Carcinoma? *Eur Urol Focus* (2020) 6:653–63. doi: 10.1016/j.euf.2019.09.003
12. Mori K, Abufaraj M, Mostafaei H, Qubal F, Karakiewicz PJ, Briganti A, et al. A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Bladder of the Bladder Treated With Radical Cystectomy. *J Urol* (2020) 204:1129–40. doi: 10.1016/j.juro.2020.01.016
13. Alvarez-Maestro M, Chierigo F, Mantica G, Quesada-Olarte JM, Carrion DM, Gomez-Rivas J, et al. The Effect of Neoadjuvant Chemotherapy Among Patients Undergoing Radical Cystectomy for Variant Histology Bladder Cancer: A Systematic Review. *Arab J Urol* (2022) 20:1–13. doi: 10.1080/2090598X.2021.1994230
14. Birtle A, Johnsen C, Jones R, Dolling D, Bryan RT, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-Label, Randomised Controlled Trial. *Lancet* (2020) 395:1268–77. doi: 10.1016/S0140-6736(20)30415-3
15. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low Incidence of Perioperative Chemotherapy for Stage III Bladder Cancer 1998 to 2003: A Report From the National Cancer Data Base. *J Urol* (2007) 178:451–4. doi: 10.1016/j.juro.2007.03.011
16. Humphrey PA, Moeh H, Cabilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. *Eur Urol* (2016) 70:106–19. doi: 10.1016/j.euro.2016.02.028
17. Chung HS, Hwang EC, Kim MS, Yu SH, Jung SI, Kang TW, et al. Effects of Variant Histology on the Oncologic Outcomes of Patients With Upper Urinary Tract Carcinoma After Radical Nephroureterectomy: A Propensity Score-Matched Analysis. *Clin Genitourin Cancer* (2019) 17:e394–407. doi: 10.1016/j.clgc.2018.11.015
18. Duplisea JJ, Petros FG, Li R, Fellman B, Guo CC, Czerniak BA, et al. Outcomes of Nonmetastatic Micropapillary Variant Upper Tract Urothelial Carcinoma. *Urol Oncol* (2019) 37:354.e319–354.e326. doi: 10.1016/j.urolonc.2019.01.026
19. Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J, Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-Analysis, and Future Perspectives on Systemic Therapy. *Eur Urol* (2021) 79:635–54. doi: 10.1016/j.euro.2020.07.003
20. Qubal F, Mori K, Sari Mottagh R, Laukhina E, Pradere B, Roupret M, et al. Efficacy of Neoadjuvant and Adjuvant Chemotherapy for Localized and Locally Advanced Upper Urinary Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis. *Int J Clin Oncol* (2020) 25:1037–54. doi: 10.1007/s10147-020-01650-9
21. Laukhina E, Sari Mottagh R, Mori K, Katayama S, Rajwa P, Yanagisawa T, et al. Chemotherapy is Superior to Checkpoint Inhibitors After Radical Surgery for Urothelial Carcinoma: A Systematic Review and Network Meta-Analysis of Oncologic and Toxicity Outcomes. *Crit Rev Oncol Hematol* (2021) 169:103570. doi: 10.1016/j.critrevonc.2021.103570
22. Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brusada A, et al. Impact of Histological Variants on Oncological Outcomes of Patients With Urothelial
Carcinoma of the Bladder Treated With Radical Cystectomy. *Eur J Cancer* (2013) 49:1889–97. doi: 10.1016/j.ejca.2013.02.001

23. Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, et al. Pathological Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. *J Urol* (2021) 206:924–32. doi: 10.1097/JU.0000000000001855

24. Vetterlein MW, Wankowicz SAM, Seisen T, Lander R, Loppenberg B, Chun FK, et al. Neoadjuvant Chemotherapy Prior to Radical Cystectomy for Muscle-Invasive Bladder Cancer With Variant Histology. *Cancer* (2017) 123:4346–55. doi: 10.1002/cncr.30907

25. Witjes JA, Babjuk M, Bellmunt J, Brüns HM, De Reijke TM, De Santis M, et al. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Efort(†): Under the Auspices of the EAU-ESMO Guidelines Committees. *Eur Urol* (2020) 77:223–50. doi: 10.1016/j.eururo.2019.09.035

26. Tully KH, Krimpjove Md MJ, Huynh MJ, Marchese M, Kibel AS, Noldus J, et al. Differences in Survival and Impact of Adjuvant Chemotherapy in Patients With Variant Histology of Tumors of the Renal Pelvis. *World J Urol* (2020) 38:2227–36. doi: 10.1007/s00345-019-03003-2

27. Zaghloul MS, Nouh A, Nazmy M, Ramzy S, Zaghloul AS, Sedira MA, et al. Long-Term Results of Primary Adenocarcinoma of the Urinary Bladder: A Report on 192 Patients. *Urol Oncol* (2006) 24:13–20. doi: 10.1016/j.urolonc.2005.05.027

28. Pearce SM, Pariser JJ, Patel SG, Steinberg GD, Shalhav AL, Smith ND. The Effect of Surgical Approach on Performance of Lymphadenectomy and Perioperative Morbidity for Radical Nephroureterectomy. *Urol Oncol* (2016) 34:121.e115–121. doi: 10.1016/j.urolonc.2015.09.008

29. Chang CH, Wu WJ, Lee HY, Lin CH, Yue CT, Jiang YH, et al. Impact of Pathology Review in Adverse Histological Characteristics and pT Stages of Upper Tract Urothelial Cancer in a Multicenter Study. *Front Oncol* (2021) 11:757359. doi: 10.3389/fonc.2021.757359

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Lo, Li, Ke, Chang, Wu, Chen, Lin, Huang, Chen, Tseng, Lin, Jiang, Lee, Tsai, Chung, Hsieh, Chiu, Jua, Choong, Chen, Chiang, Yu, Lin, Wu, Chen, Weng and Tsai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.